Drug Type Fc fusion protein |
Synonyms- |
Target |
Action agonists |
Mechanism FGF21R agonists, GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Metabolic dysfunction-associated steatotic liver disease | Preclinical | United States | 10 May 2024 |






